Tag: JenaValve
ADVERTORIAL: TAVI offers promise in the “underdiagnosed and undertreated” aortic regurgitation population
This advertorial is sponsored by JenaValve
Transcatheter aortic valve implantation (TAVI) has...
Transcatheter options for AR open up TAVI to a new patient population
Transcatheter treatment options for aortic regurgitation (AR) bring a new, less invasive approa...
JenaValve raises US$100 Million to advance Trilogy TAVI system
JenaValve Technology has announced that it has completed the initial closing of a US$100 million Ser...
JenaValve Technology appoints John T Kilcoyne as chief executive officer
Medical device executive John T Kilcoyne has been appointed as chief executive officer of JenaValve ...
JenaValve receives FDA approval for expanded IDE enrolment in the treatment of patients with severe aortic stenosis and severe aortic regurgitation
JenaValve has received US FDA approval of expansion of its investigational device exemption (IDE...
Patient enrolment in US early feasibility study of Everdur TAVI device initiated
JenaValve has announced initiation of patient enrolment in its early feasibility study (EFS) of ...
Implantation of JenaValve successful in initial patients enrolled in CE mark study
JenaValve Technology has announced the initiation of patient enrolment and implantations associa...
Study of next-generation JenaValve device completes enrolment
A press release reports that successful patient enrolment in the CE mark study of the next-gener...
